Population-based evaluation of the management of antithrombotic therapy for atrial fibrillation

Canadian Journal of Cardiology

Volumn 21, Issue 3, 2005, Pages 257-266

  Anderson, David R ^a,b,c   Gardner, Martin J ^a,b   Putnam, Wayne ^a,b   Jassal, Davinder ^a,b   Brownell, Brenda ^a,b   Flowerdew, Gordon ^a   Nagpal, Seema ^a,b   Thompson, Kara ^a,b   Cox, Jafna L ^a,b  

^a DALHOUSIE UNIVERSITY   (Canada)

^b Capital Health   (Canada)

^c QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

Author keywords

Atrial fibrillation; Management; Oral anticoagulants

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT;

ADULT; AGE DISTRIBUTION; AGED; ANTICOAGULANT THERAPY; CANADA; CARDIOVASCULAR RISK; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EFFICACY; DRUG INDICATION; DRUG USE; ELECTROCARDIOGRAPHY; EVIDENCE BASED MEDICINE; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; INTRACARDIAC THROMBOSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL SPECIALIST; OUTPATIENT CARE; PATIENT EDUCATION; POPULATION RESEARCH; PRACTICE GUIDELINE; PRESCRIPTION; PRIMARY MEDICAL CARE; REVIEW; STROKE; THROMBOEMBOLISM; TIME;

ADMINISTRATION, ORAL; ADULT; AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; COMMUNITY HEALTH PLANNING; CROSS-SECTIONAL STUDIES; DRUG UTILIZATION; EDUCATIONAL STATUS; ELECTROCARDIOGRAPHY; FAMILY PRACTICE; FEMALE; FIBRINOLYTIC AGENTS; GUIDELINE ADHERENCE; HEALTH CARE SURVEYS; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; MALE; MIDDLE AGED; NOVA SCOTIA; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES; PRESCRIPTIONS, DRUG; QUESTIONNAIRES; RISK FACTORS; SPECIALTIES, MEDICAL; THROMBOSIS;

EID: 17444431203     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (28)

1. Feinberg WM, Blackshear JL, Laupacis A, Kronmal R, Hart RG. Prevalence, age distribution, and gender of patients with atrial fibrillation: Analysis and implications. Arch Intern Med 1995;155:469-73.
2. Albers GW, Atwood JE, Hirsh J, Sherman DG, Hughes RA, Connolly SJ. Stroke prevention in nonvalvular atrial fibrillation. Ann Intern Med 1991;115:727-36.
3. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: The Framingham Study. Stroke 1991;22:983-8.
4. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med 1990;323:1505-11.
5. Connolly SJ, Laupacis A, Gent M, Roberts RS, Cairns JA, Joyner C. Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. J Am Coll Cardiol 1991;18:349-55.
6. Stroke Prevention in Atrial Fibrillation Study. Final Results. Circulation 1991;84:527-39.
7. Ezekowitz MD, Bridgers SL, James KE, et al; Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. N Engl J Med 1992;327:1406-12. (Erratum in 1993;328:148)
8. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet 1996;348:633-8.
9. EAFT (European Atrial Fibrillation Trial) Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 1993;342:1255-62.
10. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet 1994;343:687-91.
11. Petersen P, Boysen G, Godtfredsen J, Andersen ED, Andersen B. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. Lancet 1989;1:175-9.
12. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994;154:1449-57. (Erratum in 1994;154:2254)
13. Albers GW, Dalen JE, Laupacis A, Manning WJ, Petersen P, Singer DE. Antithrombotic therapy in atrial fibrillation. Chest 2001;119(1 Suppl):194S-206S.
14. Antani MR, Beyth RJ, Covinsky KE, et al. Failure to prescribe warfarin to patients with nonrheumatic atrial fibrillation. J Gen Intern Med 1996;11:713-20.
15. Beyth RJ, Antani MR, Covinsky KE, et al. Why isn't warfain prescribed to patients with nonrheumatic atrial fibrillation? J Gen Intern Med 1996;11:721-8.
16. Gottlieb LK, Salem-Schatz S. Anticoagulation in atrial fibrillation. Does efficacy in clinical trials translate into effectiveness in practice? Arch Intern Med 1994;154:1945-53.
17. Munschauer FE, Priore RL, Hens M, Castilone A. Thromboembolism prophylaxis in chronic atrial fibrillation. Practice patterns in community and tertiary-care hospitals. Stroke 1997;28:72-6.
18. Stafford RS, Singer DE. National patterns of warfarin use in atrial fibrillation. Arch Intern Med 1996;156:2537-41.
19. Sudlow M, Thomson R, Thwaites B, Rodgers H, Kenny RA. Prevalence of atrial fibrillation and eligibility for anticoagulants in the community. Lancet 1998;352:1167-71.
20. The Clinical Quality Improvement Network (CQIN) Investigators. Thromboembolic prophylaxis in 3575 hospitalized patients with atrial fibrillation. Can J Cardiol 1998;14:695-702.
21. Whittle J, Wickenheiser L, Venditti LN. Is warfarin underused in the treatment of elderly persons with atrial fibrillation? Arch Intern Med 1997;157:441-5.
22. Stafford RS, Singer DE. Recent national patterns of warfarin use in atrial fibrillation. Circulation 1998;97:1231-3.
23. Smith NL, Psaty BM, Furberg CD, et al. Temporal trends in the use of anticoagulants among older adults with atrial fibrillation. Arch Intern Med 1999;159:1574-8.
24. Go AS, Hylek EM, Borowsky LH, Phillips KA, Selby JV, Singer DE. Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: The anticoagulation and risk factors in atrial fibrillation (ATRIA) Study. Ann Intern Med 1999;131:927-34.
25. Gurwitz JH, Monette J, Rochon PA, Ecklet MA, Avorn J. Atrial fibrillation and stroke prevention with warfarin in the long-term care setting. Arch Intern Med 1997;157:978-84.
26. Nagpal S, Anderson DA, Putnam W, Flowerdew G, Gardner M, Cox J. Stroke prevention in hospitalized patients with atrial fibrillation: A population-based study. Can J Clin Pharmacol 2003;10:197-201.
27. Devereaux PJ, Anderson DR, Gardner MJ, et al. Differences between perspectives of physicians and patients on anticoagulation in patients with atrial fibrillation: Observational study. BMJ 2001;323:1218-22.
28. Bungard TJ, Ghali WA, McAlister FA, et al. The relative importance of barriers to the prescription of warfarin for nonvalvular atrial fibrillation. Can J Cardiol 2003;19:280-4.